BIOMAT Database Logo BIOMAT Database Logo

Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. 2008

Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
Laboratory of Virus Immunology, Research Center for AIDS, Institute for Virus Research, Kyoto University, 53, Kawaramachi, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.

We identified clinical isolates with phenotypic resistance to nevirapine (NVP) in the absence of known nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations. This resistance is caused by N348I, a mutation at the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). Virologic analysis showed that N348I conferred multiclass resistance to NNRTIs (NVP and delavirdine) and to nucleoside reverse transcriptase inhibitors (zidovudine [AZT] and didanosine [ddI]). N348I impaired HIV-1 replication in a cell-type-dependent manner. Acquisition of N348I was frequently observed in AZT- and/or ddI-containing therapy (12.5%; n = 48; P < 0.0001) and was accompanied with thymidine analogue-associated mutations, e.g., T215Y (n = 5/6) and the lamivudine resistance mutation M184V (n = 1/6) in a Japanese cohort. Molecular modeling analysis shows that residue 348 is proximal to the NNRTI-binding pocket and to a flexible hinge region at the base of the p66 thumb that may be affected by the N348I mutation. Our results further highlight the role of connection subdomain residues in drug resistance.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017422 Sequence Analysis, DNA A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis. DNA Sequence Analysis,Sequence Determination, DNA,Analysis, DNA Sequence,DNA Sequence Determination,DNA Sequence Determinations,DNA Sequencing,Determination, DNA Sequence,Determinations, DNA Sequence,Sequence Determinations, DNA,Analyses, DNA Sequence,DNA Sequence Analyses,Sequence Analyses, DNA,Sequencing, DNA
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.
April 2009, Journal of virology,
Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
January 2007, Antimicrobial agents and chemotherapy,
Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
August 2006, Antimicrobial agents and chemotherapy,
Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1.
March 1995, The Journal of infectious diseases,
Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
September 2005, Journal of virology,
Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
May 2010, Antimicrobial agents and chemotherapy,
Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
January 2004, Current topics in medicinal chemistry,
Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors.
January 2006, Antimicrobial agents and chemotherapy,
Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
December 1992, Antimicrobial agents and chemotherapy,
Atsuko Hachiya, and Eiichi N Kodama, and Stefan G Sarafianos, and Matthew M Schuckmann, and Yasuko Sakagami, and Masao Matsuoka, and Masafumi Takiguchi, and Hiroyuki Gatanaga, and Shinichi Oka
Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.
November 1996, The Journal of infectious diseases,
Copied contents to your clipboard!